January 8, 2013 at 11:16 am (Antipsychotics, Bipolar Disorder, Depression, Loose Screws Mental Health News, Mental Health/Illness, Schizophrenia)
Tags: Adasuve, agitation, Alexza Pharmaceuticals, asthma, Bipolar Disorder, Books, bronchospasm, C-reactive protein, COPD, CRP, Depression, I'd Like to Apologize to Every Teacher I Ever Had, Japan, Loose Screws Mental Health News, loxapine, marijuana, Medscape, mental health, mental illness, NICS, pot, psychosis, public school teachers, reading, Schizophrenia, teens, Tony Danza
An antipsychotic inhalation powder has been approved by the FDA for the treatment of agitation in adults with schizophrenia or bipolar I disorder. While loxapine (brand name: Adasuve) by Alexza Pharmaceuticals acts rapidly, the side effects include “bronchospasm and increased mortality in elderly patients with dementia-related psychosis,” according to Medscape. In case you don’t know, bronchospasm can lead to acute respiratory problems in people with lung disease, asthma, or COPD (chronic obstructive pulmonary disease).
Plans are for the drug to only be accessible through a medical facility with the ability to treat bronchospasms.
In related and somewhat interesting news, the Medscape article also notes that 3.2 million people in the U.S. are being treated for schizophrenia or bipolar I. “Of these, approximately 90% will develop agitation during the course of their illness.”
That’s an incredibly high number of people who develop agitation. Just sayin’.
According to an article in U.S. News & World Report, patients in a study dealing with depression seemed to have high levels of C-reactive protein (CRP), a marker for increased risk of heart and inflammatory disease. The lead researcher notes that “people with increased CRP have a two- to threefold risk of depression.” It is not clear whether CRP causes depression or is simply a sign of it. Increased levels of CRP tend to be seen in obese patients and those with chronic diseases.
“More than 21 million Americans suffer from depression, a leading cause of disability, according to Mental Health America.”
Note: the 2011 estimate of those residing in the U.S. stands at more than 311 million.
Depression is increasing among Japan’s public school teachers.
“A report by the Ministry of Education, Sports, Culture, Science and Technology shows that in 2011, around 5,200 public school teachers had to go on sick leave due to various mental illnesses, including severe depression.”
The Japan Daily Press article also notes:
“The study also highlights the fact that the main reason for the increasing depression is a school environment that puts too much workload and pressure on the teachers that they cannot have a healthy work-life balance anymore, much less deal with students, their guardians and the paper work that comes with all of these. (emphasis mine)”
I recently finished a book by actor Tony Danza called I’d Like to Apologize to Every Teacher I Ever Had in which he chronicles his yearlong stint in Philadelphia’s inner city public school system. He echoes some of these sentiments as well. After trying to teach his students, he notes that it is difficult not to get involved in their personal lives as well. In the Epilogue, Danza writes:
“…I can only do so much. Where does teaching stop, and start? Where should it? I don’t really know. To engage my students, I found that I had to become engaged in their lives, their problems, and their futures. That connection was what made the job the most rewarding. Yet it was also the intensity of that involvement that, by the end of the year, had made the job of teaching so much tougher than I’d ever expected.”
It seems that Japan’s public school teachers are no different from American public school teachers.
Although 38 states require mental health background checks, only a quarter of states actually report their statistics to the federal NICS (National Instant Criminal Background Check System).
And surprise, according to a recent study, pot could lead to psychosis in teens or teens who smoke pot can later develop psychosis. I find it interesting that teens were actually evaluated after smoking pot.
July 4, 2007 at 6:15 am (Antidepressants, Celebrities, Medicine/Meds, Mental Health/Illness)
Tags: antidepressant, Benoit, Chris Benoit, delusions, hallucinations, mental health, psychosis, rage, sertraline, wrestler, WWE, zoloft
Furious Seasons has a post on WWE wrestler Chris Benoit, who possibly may have taken Zoloft shortly before he committed the murder of his wife and child. The article on pwtorch.com that FS linked to refers to the possibility that Benoit's friend and doctor, Phillippe Astin III, may have prescribed the drug to Benoit on Friday, the day before he killed his wife.
There are definitely some funky mental issues behind Benoit's motives for killing his family, but it wouldn't surprise me if the Zoloft played a part in influencing him to do so. I recently mentioned Christopher Pittman who killed his grandparents in 2001 then proceeded to set their house on fire when he was on an adult dosage of 200 mg of Zoloft. He was 12. Stephany of soulful sepulcher commented that her daughter suffered from a similar problem while on 150 mg Zoloft:
Pittman was about the same age my daughter was then, and she was on 150mg of Zoloft a day, and that med changed her personality into a full blown all day raging person. She had to go inpatient to get off of it, and once off of it, she's never raged like that again. The Pittman story is very sad, as are all of the others associated with antidepressant use and teen violence. Columbine had Luvox, there's Accutane–it's beyond me how this can be overlooked in connection.
I wonder if there are other stories floating out there now about how Zoloft – an antidepressant – has caused similar behaviors. It'd be interesting to observe whether Zoloft causes hallucinations, delusions, and psychosis.
May 1, 2007 at 5:29 pm (Blogs, Mental Health/Illness, Personal, Schizophrenia, Statistics)
Tags: Americans, Archives of General Psychiatry, CATIE, crime, diagnosis, disorder, media, mental health, mental illness, population, psychiatric, psychosis, rampage, Schizophrenia, shooting, study, TAC, Treatment Advocacy Center, USPRA, violence
The subject title is long, but – I think – apropos.
The Treatment Advocacy Center’s post, “A classic case of shooting the messenger,” has been bothering me all day. I’ve been wanting to do further research on their claim that “patients with schizophrenia were 10 times more likely to engage in violent behavior than the general public.” Funny thing is, I didn’t have to look far.
The TAC links to a summary of the CATIE violence study and surprisingly, it contradicts the TAC’s post. I couldn’t help but chuckle once I realized I could easily debunk their claims from what they considered supporting evidence.
USPRA: “Violence is no more prevalent among individuals with mental illness than the general public”
Fact: The CATIE violence study found that patients with schizophrenia were 10 times more likely to engage in violent behavior than the general public (19.1% vs. 2% in the general population).
MY TAKE: “Overall, the amount of violence committed by people with schizophrenia is small, and only 1 percent of the U.S. population has schizophrenia. Of the 1,140 participants in this analysis, 80.9 percent reported no violence, while 3.6 percent reported engaging in serious violence in the past six months. Serious violence was defined as assault resulting in injury, use of a lethal weapon, or sexual assault. During the same period, 15.5 percent of participants reported engaging in minor violence, such as simple assault without injury or weapon. By comparison, about 2 percent of the general population without psychiatric disorder engages in any violent behavior in a one-year period, according to the NIMH-funded Epidemiologic Catchment Area Study.”
This data is a little skewed here. (CLPsych or Philip Dawdy could do a better job at clarifying this for me.) First of all, “about 2 percent of the general population without psychiatric disorder engages in any violent behavior in a one-year period.” How many people does this constitute? The sentence doesn’t specify ‘without schizophrenia’; it says “without psychiatric disorder.” That means Americans who do not suffer at any given time from depression, bipolar disorder, psychosis, anxiety, schizophrenia, obsessive-compulsive disorder, postpartum depression, and the list goes on and on. Can anyone compile complete data of Americans who suffer from a psychiatric disorder? (Why do I have the funny feeling that Americans without psychiatric disorders are becoming the minority?)
In the January 1994 issue of the Archives of General Psychiatry, results of the National Comorbidity Study were released. Diagnoses from the DSM-III were applied to the participants ranging from ages 15-54. The study found that 50 percent of participants reported “one lifetime disorder” and 30 percent said they had “at least one 12-month disorder.”
That was January 1994. The American population has grown significantly since then, so I have a hunch that there's an increase in diagnosing people with psychiatric illnesses. But like I said, that’s, uh, just a hunch. (Keep in mind that the study does not include children ranging from ages 4-14 who are likely to receive ADHD and/or bipolar diagnoses.)
Humor me: Let’s take the NC study’s findings and apply it to the current estimated U.S. population (assuming that the percentage of those with a lifetime disorder has remained the same). Out of nearly 300 million Americans (July ’06 estimate), that means about 150 million Americans have at least some form of a psychiatric disorder. If 1 percent of the general population suffers from schizophrenia, that comes out to 3 million people. If we apply CATIE’s violence percentages, TAC’s right; 19.1 percent of schizophrenic patients engage in violent behavior of any kind. However, the CATIE study also says that two percent of the general population without psychiatric disorder engages in violent behavior. That means out of the remaining 150 million, 2 percent of that would be —*drumroll please* — 3 million Americans! Maybe it’s just me, but doesn’t seem 10 times likely. I could always be wrong.
Read the rest of this entry »
May 1, 2007 at 2:18 pm (Celebrities, Depression, Loose Screws Mental Health News, Mental Health/Illness, PPD, Schizophrenia, Suicide)
Tags: CATIE, Cho, Cho Seung-Hui, cutting, Depression, dissidentvoice.org, mental health, mental illness, postpartum, postpartum depression, PPD, psychosis, Schizophrenia, slit wrists, TAC, Treatment Advocacy Center, violence, Virginia Tech, VT, VTech
I haven’t done this for a while so hopefully I can pick this up again a little more regularly. (crosses fingers)
Read a heart-wrenching story in the UK Daily Mail about a mother whose postpartum depression led her to begin slitting her wrists
Tom Chaplin, singer for the band Keane, has admitted to contemplating suicide.
Tom – who was taking up to two grams of cocaine a day – revealed to Britain’s Q Magazine: “I was at the end of my tether in Japan. I was tired of my life and feeling pretty suicidal. I got off the plane and called my dad. I’d told him that I’d left the band and that I was falling apart. I checked myself into The Priory.”
Chaplin’s interesting view:
Despite his own drugs hell, Tom says it’s a personal decision to experiment with substances. He claims troubled rock star Pete Doherty should be left to take all the drugs he wants.
Tom said: “No-one’s got any right to stop him killing himself.”
An article in the Chicago Tribune on how VNS is beginning to show benefits for some patients. Which reminds me, browse on over to VNSdepression.com to learn more.
Nicholas Vakkur must have read the Treatment Advocacy Center’s post on how the CATIE study shows an increase in violent offenses by mentally ill patients (namely those with psychosis and schizophrenia). He refutes this idea on dissidentvoice.org:
Individuals with a mental illness are far more likely to be the victims, rather than the perpetrators of violence, while the vast majority of people who commit acts of violence against others are not in fact mentally ill.
This rush to stereotype individuals suffering from psychiatric illness as likely murderers is reckless and lacks credulity. Mental illness has no role in the majority of violent crimes committed in our society. Alcohol and substance abuse far outweigh mental illness as factors contributing to violence, while the strongest predictor of violent and/or criminal behavior is a past history of violence and criminality, not a major mental illness.
March 2, 2007 at 11:49 am (Antipsychotics, Medicine/Meds, Pharma)
Tags: AstraZeneca, bipolar, Decision Resources, Eli Lilly, gold standard, Lamictal, lamotrigine, meds, Olanzapine, PR, psych meds, psychosis, quetiapine, Schizophrenia, Seroquel, Zyprexa
Whee for self-promotion!
“Eli Lilly’s Zyprexa Will Remain the Clinical Gold Standard for the Treatment of Schizophrenia Through 2015”
“Clinical Gold Standard,” huh?
I can’t bring anything new to the table on this. Maybe I’m wrong, but here I go:
“For almost three decades, Decision Resources has provided in-depth research on the trends, emerging developments, and market potential in various healthcare industry sectors. Our client base is diverse – including large pharmaceutical companies, emerging biotechnology concerns, financial services, managed care organizations, and medical device manufacturers who turn to Decision Resources to help shape their strategy and master their chosen markets.
The privately-owned company offers a rich array of research publications advisory services, and consulting that make it second to none for quality, analytical depth and insight. With access to almost 10,000 thought leaders, specialists, HMO formulary directors, and general practitioners, Decision Resources’ highly-credentialed analysts are able to reconcile real-world practice with hard numbers from the industry’s most respected data sources. The resulting analysis and insights drive business decisions and commercial success within the biopharmaceutical, managed care, medical device, and financial markets.”
Here’s my assessment, take it with a grain of salt: In an attempt to fight the decline in sales from the NYT-induced Zyprexa backlash, Eli Lilly has gone on the offensive and hired Decision Resources to reinvent its star medication.
Decision Resources (DR), a privately owned company (no hyphen if a modifier ends in “-ly”), has a client base that includes large pharmaceutical companies. Ta-da! Don’t get it?
Decision Resources is not a public company; hence, in addition to not receiving federal money, it doesn’t need to report its financial dealings to the SEC. Therefore, no publicly accessible financial records of DR’s clients. They haven’t said they are an “independent” organization. Perhaps this is implied. Whatever the case may be, DR gets paid by its client base to research their products and “help shape their strategy and master their chosen markets.”
This isn’t brain science; this is on their “About Us” section of their Web site. Therefore, if Eli Lilly turns to DR and pays them to – I like DR’s wording here – “shape their strategy and master their chosen markets,” then DR is essentially a PR loudspeaker letting everyone know that Zyprexa is the “clinical gold standard” for schizophrenia.
What a bunch of hooey.
Not too long ago, it seems that AstraZeneca (AZ) may have had DR engineer its new marketing strategy to give Seroquel a boost. Why not? Mental health media watchdogs are hatin’ on the atypical antipsychotics.
“According to a new report entitled Schizophrenia: Turning Physician Insight into Projected Patient Share, Zyprexa is superior in efficacy to all other current therapies, particularly on measures that are most important to prescribers, such as impact on global symptoms and responder rate.”
Holla at me if you’ve got your hands on that report mentioned above.
“In spite of scoring* less favorable than the other drugs in terms of safety and lower than risperidone in terms of delivery features, Zyprexa is the gold standard.”
OK – so it’s not safe and it doesn’t deliver as well as Risperdal – whatever that means – but Zyprexa is still “the gold standard”?
“This overall advantage for a drug with significant safety concerns highlights the importance of efficacy to prescribers.”
I want you to reread that: ” This overall advantage for a drug with significant safety concerns highlights the importance of efficacy to prescribers.” Let’s attempt to paraphrase this: The benefit of this potentially harmful drug shows the importance of how effective it is to those who receive the drug. Although Zyprexa has “significant safety concerns,” the drug works well enough for doctors to prescribe it to patients. Uh, no. Positives don’t outweigh the negatives. It was nice jargon for a second there, though. (If this is effed up enough for adults, why subject children to this crap?)
“The report also finds that the most commercially important emerging antipsychotics (Janssen’s Invega, Organon BioSciences’ asenapine, and Wyeth/Solvay/Lundbeck’s bifeprunox) score* lower than Zyprexa, indicating that Zyprexa will remain unsurpassed during Decision Resources’ forecast period.”
I know I’m doing a play-by-play but this is important. I need to find out how DR decided that Zyprexa would be the “gold standard” until 2015. (
What’s the significance of this year? Does EL’s patent on Zyprexa expire then? Nope, Eli Lilly’s patent on Zyprexa expires in 2011. Expect a similar molecularly structured olanzapine before then. Biolexapine?) So basically, in this report, DR’s conclusion is Zyprexa beats every other atypical antipsychotic for schizophrenia by far. Notice that AZ’s Seroquel (the soon-to-be “gold standard” of bipolar meds), an atypical also used for schizophrenia, is not listed. Not coincidence.
The little asterisk (*) next to the word “score” prompts me to wonder: Just how did they come up with these scores? Well, the asterisk tells me that I need to contact DR for the methodology behind the product scores. I just might. Then send it off to CL Psych or Furious Seasons to decipher the crap out of it.
Another thing to note on this PR:
“”Invega is a metabolite of risperidone and is likely to have efficacy similar to that of risperidone, which scored* slightly lower than Zyprexa overall,” said Nitasha Manchanda, Ph.D., analyst at Decision Resources. “Asenapine also lacks the differentiation to replace Zyprexa as the gold standard because it does not make as significant an impact on global symptoms, and bifeprunox is significantly inferior to Zyprexa in all primary efficacy measures and is not capable of surpassing Zyprexa.””
Dr. Manchanda, analyst for DR, pulled bifeprunox – not yet on the drug market – into the Zyprexa comparison and somehow was able to call it “significantly inferior to Zyprexa” with an incapability to “surpass” it. How many people have used bifeprunox, Ms. Manchanda? OK, now tell me how many people have used Zyprexa? And you’re telling me that a drug that hasn’t yet hit the market is “significantly inferior” to a drug that has been on the market for the past couple of years and has 1,200 lawsuits still pending in addition to the millions that have already been paid?
As for AZ, DR has determined that Seroquel will become the “gold standard” for bipolar medication by 2010, knocking Lamictal out of its current “gold standard” status. Like Furious Seasons, I had NO idea Lamictal was held up so highly for bipolar meds. Considering that lithium has always been the king of bipolar meds and treats both acute mania and depression better than Lamictal, I’m surprised to read this.
“According to the new DecisionBase report entitled Bipolar Depression: Turning Physician Insight into Projected Market Share, Seroquel’s advantages over Lamictal include the more profound effect on depressive symptoms seen in short-term trials.”
My doctor precribed Lamictal to me for management of depressive symptoms in bipolar disorder. He conversely prescribed Seroquel for mania (and to help me get sleep). Getting back to the short-term trials, Lamictal was tested for 18 months for long-term management of bipolar disorder. Seroquel, however, was tested for 8 weeks. Effective for the short-term? Perhaps. But most patients on atypicals take them long-term. And that’s precisely where Seroquel fails.
“The drug’s efficacy on this measure differentiates it from other therapies, according to thought-leading psychiatrists, and the importance assigned to this measure by prescribing psychiatrists drives Seroquel’s product score above Lamictal’s.*”
According to thought-leading psychiatrists who probably function as consultants and analysts for “large pharmaceutical companies.” Seroquel may have the potential to sell more than Lamictal by 2010 – if this is what DR’s gauging. However, it seems like DR is trying to push Seroquel, not just as a better market share, but as a better product. In this “report,” DR also fails to compare Seroquel’s efficacy to Zyprexa’s. What a convenient absence for a product used for psychosis in bipolar disorder.
(ignore any spelling errors in this post. it’s late and i bumped my forehead against the edge of a car door in the rain. ouch.)
February 5, 2007 at 3:38 am (Bipolar Disorder)
Tags: 296.2, bipolar, Bipolar Disorder, bipolar episode, Depression, depressive, depressive episodes, diagnosis, Effexor, ICD-9, ICD-9-CM, major depressive disorder, mania, manic-depressive, psychosis, terminology, venlafaxine
I came across a situation recently in which a woman was described having mania in bipolar disorder, but was “diagnosed” with 296.2. And the recommended treatment? Venlafaxine (Effexor).
I swear, sometimes doctors themselves don’t even know what to prescribe.
UPDATE: Okay, maybe I was wrong?
2007 ICD-9-CM Diagnosis 296.2
Major depressive disorder single episode
* 296.2 is a non-specific code that cannot be used to specify a diagnosis
* 296.2 contains 72 index entries
* View the ICD-9-CM Volume 1 296.* hierarchy
* Depressive psychosis, single episode or unspecified
* Endogenous depression, single episode or unspecified
* Involutional melancholia, single episode or unspecified
* Manic-depressive psychosis or reaction, depressed type, single episode or unspecified
* Monopolar depression, single episode or unspecified
* Psychotic depression, single episode or unspecified
So it’s totally possible to have a bipolar episode and be depressed? WTF? Am I depressed with bipolar symptoms or am I bipolar with depressive episodes? Ugh, none of this diagnosis stuff makes sense. Glad I’m not a doctor now.
January 26, 2007 at 10:17 am (Antipsychotics, Bipolar Disorder, Medicine/Meds, Pharma)
Tags: Abilify, advertisements, Antipsychotics, Aripiprazole, atypical antipsychotic, atypicals, bipolar, Bipolar Disorder, bipolar I, intueri, manic, marketing, medication, meds, mixed episodes, pharmaceutical companies, phone booth, psych meds, psychosis, public telephones
Oh. My. Goodness.
Intueri originally wrote the post about seeing Abilify on the side of a phone booth. I thought it was pretty funny and pretty stupid.
I still find it stupid, but even more so now.
I was on the bus heading to work today (I don’t normally take it) . When it reached a red light near the subway, I saw a telephone booth – akin to the one that you see on the right – draped in an Abilify ad. The ad is exactly what you see here. (If you can’t see it, go to Abilify.com and click on the “see our print adverisement!”)
I work near two major colleges with students who all have cell phones. Adults in the area are too busy thinking about their own problems while heading into the subway. (They, too, are likely to own cell phones.) Public telephones are rarely used anymore. So who’s going to read an ad on Abilify, let alone on a public telephone booth?
Some marketing person at Bristol-Myers Squibb probably thought it would be awesome to have an ad for Abilify near two major colleges. “All the college kids that walk by will see it!”
The readable text – from the bus, anyway – was “Treating bipolar disorder takes understanding.”
Understanding of what? Who’ll actually stand there and go, “Yeah, I need understanding” and walk right up to it to read more.
- “where you’ve been
- where you want to go
- how you want to get there”
I’m ready to understand my history, my future, and the plans I should make. Uh-huh, Abilify will help me do that.
“Ask your doctor or health care professional if ABILIFY is right for you.” [emphasis mine]
The bus didn’t stay there long enough for me to see if they included the safety information, but here’s the gist of what they provide:
- “Acute manic and mixed episodes associated with Bipolar I Disorder
- Maintaining efficacy in patients with Bipolar I Disorder with a recent manic or mixed episode who had been stabilized and then maintained for at least 6 weeks “
Someone can explain the last part to me a little better? I’m a mixed-episode case, do I qualify for Abilify?
I was under the impression that Abilify (aripiprazole) is an atypical antipsychotic. Antipsychotics should be prescribed for those who have psychosis. (I may be wrong here; I’m still trying to figure out the difference between typical and atypicals.) I don’t have psychosis. I don’t need Abilify. But the few bipolar people who will read that ad – they’re likely to be homeless – will be misled into thinking that they need Abilify to help them. They’ll go their doctors, saying, “I’ve heard Abilify helps people with bipolar disorder, could I perhaps try it?” PCPs will immediately churn out prescriptions and uneducated psychiatrists (yes, they are out there despite their degrees) will say, “Sure, Abilify works for bipolar disorder. Let’s see if it works for you.” The smart psych would say, “I’m not sure if it would be right for you. It’s an atypical antipsychotic that targets Bipolar I patients who have symptoms of psychosis. Let’s try something else instead.”
So I went on my soapbox. Again. But it angers me to see:
- An Abilify ad on a phone booth. Period.
- A misleading advertisement geared to all people with bipolar disorder (it doesn’t specify until you get to the fine print) that says, “Try this; it may work for you.”
- An advertisement for medication. At all.
What’s next? A marketing blitz by Eli Lilly? “Zyprexa doesn’t cause diabetes! Check out zyprexafacts.com for more information!”
Big Pharma never fails to surprise me.
January 22, 2007 at 4:19 pm (Antipsychotics, Medicine/Meds, Mental Health/Illness, Schizophrenia)
Tags: antypical antipsychotic, atypicals, bifeprunox, dopamine, medication, psych meds, psychosis, Schizophrenia, Wyeth
Someone get this on Furious Seasons’ radar:
Wyeth is also in development for an atypical antipsychotic, bifeprunox, for schizophrenia. Bifeprunox has no trade name yet.
“Bifeprunox, a dopamine partial agonist, is an investigational atypical antipsychotic for the treatment of schizophrenia. Clinical data were presented from safety and efficacy studies that evaluated bifeprunox for the treatment of schizophrenia in both acutely psychotic patients and patients who have stabilized disease.
While bifeprunox has been shown to have a smaller mean effect in acute psychosis when compared with older atypical antipsychotics that have some well-known side effects, it may be particularly well-suited for patients who are experiencing side effects with their current therapy. The safety data for bifeprunox have consistently shown a favorable weight and metabolic profile in both short- and long-term studies, which is a common and serious side effect that can cause patients to stop taking their medication.”
A few questions on Wyeth’s schizo drug:
- How long before this is marketed to bipolar I’s with psychosis?
- Older atypical antipsychotics or older typical antipsychotics?
- I’d like to see the data on weight and metabolic profiles on this. Most APs don’t have a good track record with weight, i.e. Seroquel, Abilify, Zyprexa.
Bifeprunox will developing over the coming months and years. I’ll probably check out clinicaltrials.gov in the future to check on updates.
January 18, 2007 at 9:18 pm (Antidepressants, Antipsychotics, Bipolar Disorder, Children, Depression, Loose Screws Mental Health News, Medicine/Meds, Mental Health/Illness, Personal, Pharma)
Tags: anxiety, bipolar, Bipolar Disorder, black-box warning, blood sugar, dementia, depressed, Depression, diabetes, Eli Lilly, FDA, hyperglycemia, infant depression, Jack B. Weinstein, Lilly, mania, manic, manic-depression, mental health, mental illness, mirtazapine, off-lable, Olanzapine, psychosis, psychotic, PTSD, remeron, weight gain, zispin, Zyprexa
Starting off with some crazy (npi) mental health news, psychotherapists are now beginning to diagnose depression and anxiety in – infants. Yes, infants. Before you know it, newborns will begin suffering from post-traumatic stress disorder after enduring complications during delivery. Fetuses will suffer from depression due to lack of exposure to light.
I’m all for diagnosing mental illness in children, but infant depression? Unless it’s mistreated, the concept is ridiculous.
“He says he doesn’t put babies on the couch. Instead, he observed Jayda through a one way mirror. He was looking for clues on why she wouldn’t bond with her mother, Kari Garza.”
“Psychologist Douglas Goldsmith says ‘even by the first birthday, some of the research is saying we should be able to start to see signs of more serious social disorders.’
There are some warning signs to look out for, such as a lack interest in sights and sounds. Others include of lack of desire to interact; listlessness; or excessive crying.”
I can’t help but think it’s rooted in a physical rather than a mental problem. I excessively cried for six months as an infant; no knew that I’d developed eczema and the itching was unbearable because I wasn’t able scratch.
“Figuring out what’s depression versus normal behavior is hard, according Pediatrician Linda Nelson of the Franciscan Children’s Hospital, because ‘the crankiness and all of that, teasing that out from true depression, it’s very difficult.'”
Josh of “We Worry” writes:
“I may be way off the mark on this one, but if Iâm not mistaken, an infantâs cognitive abilities are incredibly limited and, for the most part, are dictated entirely by instinctual behaviors. It seems that it would be impossible to determine if an infant had depression or anxiety because itâs impossible to ask them.”
Nope, not off the mark at all.
Want to know what dealing with a bipolar is like? The following is dead on
“Bipolar is a hell of a disease, and I wonder if patients [at my community health center job] knew how devastating it is, whether they’d choose to label themselves that way.
Bipolar used to be called manic-depression. People with bipolar disorder are constantly on a roller coast ride between severe depression and mania. On the depressed end, this can include feelings of worthlessness, excessive guilt, changes in eating (over- or under-), changes in sleep patterns (can’t go to sleep or can’t wake up), and recurrent thoughts of death.
On the manic end, bipolar people experience feelings of grandiosity, believing they’re capable of things nobody can do. At this end of the spectrum they often sleep very little, their thoughts race, and they can’t stop talking. They tend to get involved in risky activities, such as unrestrained buying sprees, sexual indiscretions, or foolish business investments. Some feel more angry than expansive in their manic phase, or when they’re on their way up or down.”
Congrats. You get the gold star. You’ve just learned something today (if you’re not bipolar).
I recently read Graham’s Blog
and among a list of meds
, I saw “Zispin.”
It’s trademarked as Remeron in the U.S. and Zispin in Great Britain. The generic name is mirtazapine. Sounds like a name for a German lady – Fraulein Mirtazapine.
According to the wonderful wikipedia, mirta treats “mild to severe” depression.” That’s a wide spectrum of patients to cover. Mirta is as effective for people with mild depression as it is for those who are dang near suicidal everyday? I’m not convinced.
Of course, since it’s a med, it’s used off-label for panic disorder, GAC, OCD, and PTSD among other health problems.
If you’re you suffer from bipolar and get a prescription for this stuff, get another doctor quick: mania is a side effect.
I won’t get into the fine details of how mirta works, but it appears that it enhances neurotransmitter actions rather than affect serotonin levels directly.
There’s my new medication lesson of the day.
I’m late on the bandwagon, here. I’m sure Furious Seasons
, CL Psych
, and other blogs have railed on the injustice of Judge Weinstein’s stupid –
yes, it is stupid –
decision to uphold his gag order
(he imposed it so why would he change it?) that keeps blogs from “dissemination” Eli Lilly’s leaked documents. Basically, the judge wants to block wiki Zyprexa Kills
from showing this info. Any other blog that has the documents, links to it, or publishes it is â well â subject to a gag order as well. *gag*
I have a personal opinion on the matter and since you’re reading this blog, you’ll be subjected to it.
Read the rest of this entry »
January 5, 2007 at 8:19 am (Antipsychotics, Medicine/Meds, Mental Health/Illness, News, Pharma)
Tags: Alex Berenson, Berenson, bipolar, Bipolar Disorder, death, diabetes, drug, Eli Lilly, heart disease, hyperglycemia, Kauffman, Lilly, medication, meds, mental health, mental illness, mentally ill, New York Times, NYT, obesity, Olanzapine, psych meds, psychosis, Schizophrenia, settlement, weight gain
More on Zyprexa, folks. It just isn't going to go away.
NYT reporter Alex Berenson, continuing his stellar coverage of Zyprexa's risks and exposing Eli Lilly's deceitfulness, has uncovered a recent case of a man who died using Zyprexa. John Eric Kauffman has a complicated medical, which might have led to his death. However, he was a mentally ill patient on Zyprexa and as a result of his death, Eli Lilly must report his death to "federal regulators," which it is required to do under law. However, despite his heavy smoking, he gained 80 lbs. on Zyprexa – which possibly led him to develop heart disease and become sedentary after being active most of his life. His mother says that Zyprexa did help him stave off the psychosis of his bipolar disorder, but his mother wonders if the risk was worth the early death of her son. Kauffman at 41 years old weighed 259 lbs. at the time of his death. He was 5' 10".
Which leads to the question of whether mentally ill patients should choose between taking Zyprexa – which CAN help mentally ill people – and dealing with its significant side effects or risk not taking Zyprexa when other medications won't work. In light of all this, should a doctor even continue to prescribe Zyprexa after seeing its awful side effects but left with no other choice (given that a patient is treatment-resistant to most medications)?
Eli Lilly's response to this continues to be appalling:
"Zyprexa is a lifesaving drug and it has helped millions of people worldwide with schizophrenia and bipolar disorder regain control of their lives."
It may be true that it helps people "regain control of their lives," but as for being a lifesaving drug – that's unlikely. Zyprexa has been shown to induce diabetes, obesity, hyperglycemia, and now, heart disease and death. I commend Australian regulators for looking into the details of Lilly downplaying the risk of Zyprexa and hope that they will make the information public – a different course than what the U.S. federal government seems to be taking. Lilly's 2006 settlement with patients who developed diabetes and other health problems is pure evidence that despite their constant denials, Lilly's hiding something in an effort to make profits.
My prediction: The FDA will eventually slap a black-box warning on Zyprexa, warning patients that it makes them more prone to diabetes and its other ill health effects.
December 25, 2006 at 8:18 am (Blogs, Medicine/Meds, Mental Health/Illness, News, Schizophrenia)
Tags: articles, blog, Conan Doyle, ECT, hallucinogen, magic mushroom, News, OCD, psychosis, schizophrenic, Sherlock Holmes, Spikol, Trouble With Spikol
Liz Spikol found an article that says Sir Arthur Conan Doyle (author of Sherlock Holmes) could have been schizo. I diagnose him as bipolar with symptoms of psychosis. Really, this many years later, what does it matter? What could we do for him now?
Also from Liz Spikol, she mentions an article that now says ECT (electroshock therapy) is possibly bad for depression. Spikol has mentioned going through ECT in the past and has complained that it has impaired her cognitive functioning and memory. Looks like she’s no longer alone.
Supposedly, the hallucenogenic in magic mushrooms can help stave off severe OCD for four hours up to a full day with reports of effects lasting up to a few days. But there’s no definitive proof since the clinical trial was only used with 9 people.
I guess ya’ll should just head on over to Spikol’s blog because I think I found the last three articles from her. Here: The Trouble With Spikol
December 18, 2006 at 1:44 pm (Depression, Medicine/Meds, Mental Health/Illness, News, Personal, Pharma)
Tags: bipolar, Bipolar Disorder, celexa, dementia, Depression, dosage, drug reps, Effexor, Effexor XR, elderly, Eli Lilly, escitalopram, Lamictal, lamotrigine, Lexapro, Lilly, lithium, medication, meds, mental health, mental illness, Olanzapine, paroxetine, patients, Paxil, PCPs, prescribing, prescriptions, primary care physicians, psych hospital, psych meds, psychiatrists, psychosis, quetiapine, Schizophrenia, seniors, Seroquel, suicidal ideation, suicidal thoughts, Suicide, venlafaxine, Zyprexa
Eli Lilly’s actions continue to be appalling.
Apart from trying to hide the fact that Zyprexa induces weight gain, diabetes, and hyperglycemia, they also had sales reps encourage primary care physicians to prescribe Zyprexa for patients who did not have schizophrenia or bipolar disorder (basically off-label usage).
It seems that Lilly told marketing reps to suggest Zyprexa for dementia in the elderly. Lilly denies this, of course, since olanzapine (Zyprexa’s generic name) is not approved for that kind of use since it increases the risk of death in seniors with psychosis associated with dementia. Lilly also attempted to market olanzapine to patients with mild bipolar disorder who suffer mainly from depression. (In actuality, Zyprexa is approved to treat those who suffer from mania.)
This issue with Eli Lilly delves into precisely why I am against PCPs prescribing psychiatric medicines. Primary care physicians don’t know enough about the various psychiatric conditions to prescribe the appropriate kind of medication. This type of prescription should be left to specialists like psychiatrists. PCPs should focus on the things they deal with on a daily basis that no one else can take care of: the common cold, the flu, annual physical, etc. It should be the job of the PCP to refer a patient to a psychiatrist should they present symptoms of mental illness (depression, schizophrenia, etc.). I have been burned by having a PCP prescribe antidepressants for me and as a result, attributed my horrible experience with drugs to that.
Read the rest of this entry »